Patents Represented by Attorney, Agent or Law Firm Jasbir Sagoo
-
Patent number: 6780409Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the subthalmic nucleus of the basal ganglia, mesaphilia and thalmus.Type: GrantFiled: May 23, 2001Date of Patent: August 24, 2004Assignees: Thomas Jefferson University, Neurologix, Inc.Inventors: Matthew J. During, Michael Kaplitt
-
Patent number: 6753181Abstract: The invention is directed to methods for producing a decellularized organ or part of an organ. A decellularized organ is produced using an isolated organ mechanically agitated to remove cellular membranes surrounding the isolated organ without destroying the interstitial structure of the organ. After the cellular membrane is removed, the isolated organ is exposed to a solubilizing fluid that extracts cellular material without dissolving the interstitial structure of the organ. A washing fluid is used to remove the solubilized components, leaving behind a decellularized organ.Type: GrantFiled: March 5, 2002Date of Patent: June 22, 2004Assignee: Children's Medical Center CorporationInventor: Anthony Atala
-
Patent number: 6699968Abstract: A purified mammalian proteoglycan, and genetic information encoding such proteoglycans, having a core polypetide molecular weight of about 30 kD to about 35 kD, and comprising a hydrophilic amino terminal extracellular region, a hydrophilic carboxy terminal cytoplasmic region, a transmembrane hydrophobic region between said cytoplasmic and extracellular regions, a protease susceptible cleavage sequence extracellularly adjacent the transmembrane region of the peptide, and at least one glycosylation site for attachment of a heparan sulfate chain to said extracellular region, said glycosylation site comprising a heparan sulfate attachment sequence represented by a formula Xac-Z-Ser-Gly-Ser-Gly (SEQ ID NO: 44), where Xac represents an amino acid residue having an acidic sidechain, and Z represents from 1 to 10 amino acid residues. Additional peptides having this glycosylation site and genetic information useful for preparing a number of variations based on this glycosylation site are also provided.Type: GrantFiled: November 28, 2000Date of Patent: March 2, 2004Assignee: Children's Medical Center CorporationInventors: Scott Saunders, Merton Bernfield, Masato Kato
-
Patent number: 6673339Abstract: The invention is directed to a prosthetic kidney, to methods of making a prosthetic kidney and to methods of treating kidney disease with a prosthetic kidney. The prosthetic kidney comprises nephron analogs on the exterior surface and an enclosed porous membrane structure equipped with an effluent channel for collecting and draining urine from the device. The nephron analogs are prepared by implanting a device containing renal tubule analogs on the membrane structures and inducing angiogenesis to form glomeruli-like structures. The renal tubule analogs are prepared by seeding kidney cells on the porous membrane structure and culturing this composite in vitro.Type: GrantFiled: May 26, 1999Date of Patent: January 6, 2004Assignee: Children's Medical Center CorporationInventors: Anthony Atala, James J. Yoo, Samy Ashkar
-
Patent number: 6576019Abstract: The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of the luminal organ or tissue structure with a first cell population on or in a first area and a second cell population such as a smooth muscle cell population in a second area of the polymeric matrix. The method involves grafting the device to an area in a patient in need of treatment. The polymeric matrix comprises a biocompatible and biodegradable material.Type: GrantFiled: July 17, 2000Date of Patent: June 10, 2003Assignee: Children's Medical Center CorporationInventor: Anthony Atala
-
Patent number: 6547719Abstract: A cartilaginous structural member (CSM) for use in penile reconstruction, for the correction of developmental defects, postoperative reconstruction, and for reconstructive preprosthetic surgery. The cartilaginous structural member (CSM) comprise of live cells seeded onto pre-formed shaped structure which may be biodegradable. The live cells may comprise chondrocyte and the cartilaginous structural member (CSM) for use in reconstructive surgery may be constructed of polyglycolic acid. The implant structure is applicable to use for the regeneration and reconstruction or augmentation of semirigid members of the body such as the penis, nose, ear and locations which naturally has cartilage. Further, the cartilaginous structural member (CSM) may be used in plastic surgery such as, for example, breast augmentation or pectoral augmentation.Type: GrantFiled: July 31, 2000Date of Patent: April 15, 2003Assignee: Children's Medical Center CorporationInventors: Anthony Atala, James J. Yoo
-
Patent number: 6535823Abstract: A method and apparatus is disclosed for determining the oxidative stability of pure lipids or lipids incorporated into complex matrices containing other, non-lipid ingredients. An exemplary test system includes a first container adapted to contain the sample and a heater for heating the sample to make it give off an effluent gas. A second container contains a collection fluid through which the effluent gas can be passed. A sensor within the second container measures pH, acetate, ammonia, and/or formate. An optional computation device in communication with the one or more sensors determines a point in time at which the level of one of pH, acetate, formate and/or ammonia changes suddenly.Type: GrantFiled: July 1, 1999Date of Patent: March 18, 2003Assignee: Omnion, Inc.Inventor: Frank McGovern
-
Patent number: 6531295Abstract: A purified mammalian proteoglycan, and genetic information encoding such proteoglycans, having a core polypetide molecular weight of about 30 kD to about 35 kD, and comprising a hydrophilic amino terminal extracellular region, a hydrophilic carboxy terminal cytoplasmic region, a transmembrane hydrophobic region between said cytoplasmic and extracellular regions, a protease susceptible cleavage sequence extracellularly adjacent the transmembrane region of the peptide; and at least one glycosylation site for attachment of a heparan sulfate chain to said extracellular region, said glycosylation site comprising a heparan sulfate attachment sequence represented by a formula Xac-Z-Ser-Gly-Ser-Gly, where Xac represents an amino acid residue having an acidic sidechain, and Z represents from 1 to 10 amino acid residues. Additional peptides having this glycosylation site and genetic information useful for preparing a number of variations based on this glycosylation site are also provided.Type: GrantFiled: June 6, 1995Date of Patent: March 11, 2003Assignee: Children's Medical Center CorporationInventors: Scott Saunders, Merton Bernfield, Masato Kato
-
Patent number: 6514292Abstract: A prosthetic corporal cavernosal structure (PCCS) for use in penile reconstruction, for the correction of developmental defects, for postoperative reconstruction, and for reconstructive preprosthetic surgery. The prosthetic corporal cavernosal structure (PCCS) comprises live cells seeded onto pre-formed shaped structure which may be biodegradable. The live cells may comprise smooth muscle cells such as corporal cavernosal cells, and the prosthetic corporal cavernosal structure (PCCS) for use in reconstructive surgery may be constructed of polyglycolic acid. The implant structure is applicable to use for the regeneration and reconstruction or augmentation of semirigid erectile members of the body such as the penis, and the clitoris.Type: GrantFiled: November 21, 2000Date of Patent: February 4, 2003Assignee: Children's Medical Center CorporationInventor: Anthony Atala
-
Patent number: 6503887Abstract: The invention provide methods and compositions for targeting endocrine cells capable of converting an immature expressed protein into a mature protein, and secreting the expressed protein into the systemic circulation. In particular, the invention features methods and compositions for treating disorders, such as diabetes by orally administering a vector expressing insulin to target cells which can subsequently secrete the expressed insulin into the blood circulation.Type: GrantFiled: February 22, 2000Date of Patent: January 7, 2003Inventor: Matthew J. During
-
Patent number: 6482645Abstract: The present invention describes methods for producing artificial fascial slings and their subsequent use in treating subjects with urinary incontinence. The invention is based, in part, on the discovery that mesenchymal cells that secrete elastin and collagen, extracellular proteins responsible for elasticity and strength, respectively, can be used to engineer artificial fascia in vitro.Type: GrantFiled: March 5, 2002Date of Patent: November 19, 2002Assignee: Children's Medical Center CorporationInventor: Anthony Atala
-
Patent number: 6479064Abstract: artificial organs are reconstructed using a three-dimensional scaffold produced by decellularizing biostructures from a donor organ. The three-dimensional scaffold is perfused with isolated endothelial cells that develop to produce an endothelial tissue layer with a primitive vascular system that sustains the growth and development of a second cultured cell population. When grown in the three-dimensional scaffold containing the endothelial tissue layer, with the primitive vascular system, the cells of the second cell population proliferate, mature and differentiate into neomorphic organ structures that are analogous to their in vivo counterparts.Type: GrantFiled: December 29, 1999Date of Patent: November 12, 2002Assignee: Children's Medical Center CorporationInventor: Anthony Atala
-
Patent number: 6428802Abstract: Compositions and methods are provided for producing multilayered artificial organs comprising heterogenous polylayers. Polylayers comprising homogenous cell populations are created on one side of a biocompatible substrate such that a chimeric interface is produced between the heterogenous polylayers. Cellular interaction at the chimeric interface produce an interstitial biomaterial with morphological and functional characteristics that resemble the natural in vivo organ. An artificial organ is produced by creating a first cultured polylayer of cells derived from an isolated population of smooth muscle cells on a substrate in the shape of an organ, and creating a second cultured polylayer of cells derived from a cell population different from the smooth muscle cell population.Type: GrantFiled: December 29, 1999Date of Patent: August 6, 2002Assignee: Children's Medical Center Corp.Inventor: Anthony Atala
-
Patent number: 6376244Abstract: The invention is directed to methods for producing a decellularized organ or part of an organ. A decellularized organ is produced using an isolated organ mechanically agitated to remove cellular membranes surrounding the isolated organ without destroying the interstitial structure of the organ. After the cellular membrane is removed, the isolated organ is exposed to a solubilizing fluid that extracts cellular material without dissolving the interstitial structure of the organ. A washing fluid is used to remove the solubilized components, leaving behind a decellularized organ.Type: GrantFiled: December 29, 1999Date of Patent: April 23, 2002Assignee: Children's Medical Center CorporationInventor: Anthony Atala
-
Patent number: 6368859Abstract: The present invention describes methods for producing artificial fascial slings and their subsequent use in treating subjects with urinary incontinence. The invention is based, in part, on the discovery that mesenchymal cells that secrete elastin and collagen, extracellular proteins responsible for elasticity and strength, respectively, can be used to engineer artificial fascia in vitro.Type: GrantFiled: December 29, 1999Date of Patent: April 9, 2002Assignee: Children's Medical Center CorporationInventor: Anthony Atala